Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study.
about
G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsivenessDuchenne muscular dystrophy: current cell therapiesBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Impact of Charged Particle Exposure on Homologous DNA Double-Strand Break Repair in Human Blood-Derived Cells.Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering.Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201Bone marrow endothelial progenitors in atherosclerotic plaque resolutionHematopoietic stem cell mobilization: updated conceptual renditionsThe novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.Donors' health state the year after peripheral haematopoietic progenitor cell collection: A prospective follow-up study in related and unrelated donors compared to first-time platelet donors.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation.Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors.Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.Effective collection of peripheral blood stem cells in children weighing 20 kilogram or less in a single large-volume apheresis procedure.Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation.Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.
P2860
Q34473816-E1335D9D-9F2D-46BC-972D-0F9A44CDCAC9Q35213695-B705B57D-96B4-4949-88B6-4FBBD1EB932FQ35780806-92790713-C3AA-4024-BAAF-08681BA5CE07Q35835005-1AE005F3-A47C-4775-9FB0-5A36AD836081Q36270627-9D48D66F-239B-4D4E-8DB5-535F967FEE66Q36428933-48BE5A86-306E-4951-9142-34DFFEA36D41Q36902128-31B1C535-C785-4959-88D1-99C4372F26C8Q36906139-94037250-E3A3-41D3-9FBF-922C86CC4E2FQ36912472-67DEF0F2-F478-44DA-A3BA-D67D4FE57B97Q37397999-8E6CD9D9-CC91-4746-A1B5-E99C1194CD19Q37554951-C62363E4-4B7F-4F04-A4AC-2B81D27C37F4Q38323097-6A5A7491-0DC2-4218-95EC-D0EAC20A99A9Q38712374-C171DFC8-F43D-4024-8F50-2895043A02FEQ39385304-003C4307-10CD-4207-957C-66573252A1B4Q40697115-32110041-ED2F-4A4A-AA89-C56984B4E57DQ40727125-41F4EE1B-90F9-402C-BCD5-83AAD78FF6F9Q48192483-12A8BBB8-3685-470F-A3F4-3C10D39618DBQ50454066-9CE49A46-D172-4441-8FD6-DFA686B35DC6Q50463607-58770F8A-C1C1-450F-B69B-21A966301AF0Q55280499-EB3FF6C2-D6D6-4CAC-AC12-C6FD02B518DE
P2860
Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@en
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@nl
type
label
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@en
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@nl
prefLabel
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@en
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@nl
P2093
P2860
P1433
P1476
Safety and efficacy of healthy ...... udinal 5-year follow-up study.
@en
P2093
E Seifried
H Bialleck
M M Mueller
S Brauninger
P2860
P356
10.1111/J.1423-0410.2012.01632.X
P577
2012-07-24T00:00:00Z